After several years of IPO drought in the biotech industry, the public market is picking up again. Will the trend keep going in 2026?
1. Nature Biotechnology published the letter, which 165 biotech executives signed, that details the industry’s “deep concern and opposition to the executive order.” 2. The letter says of the nearly 69 ...
Welcome to another edition of Core Biotech!I started this portfolio with the objective of proving that Long-Term investing in the biotech sector is a worthwhile endeavor.New buys and sells are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results